Genetic polymorphisms of the drug-metabolizing enzyme cytochrome P450 3A5 in a Uyghur Chinese population

References

• Adamec C. (1964). Example of the use of the nonparametric test. Test X2 for comparison of 2 independent examples. Ceskoslovenské Zdravotnictví 12:613–19
   PubMedGoogle Scholar
• Bains RK, Kovacevic M, Plaster CA, et al. (2013). Molecular diversity and population structure at the cytochrome P450 3A5 gene in Africa. BMC Genet 14:1–18
   PubMed Web of Science ®Google Scholar
• Balram C, Zhou Q, Yin BC, Lee EJD. (2003). CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 59:123–6
   PubMed Web of Science ®Google Scholar
• Du RYV. (1993). Ethics groups in China. Beijing, China: Science Press
   Google Scholar
• Elmachad M, Elkabbaj D, Elkerch F, et al. (2012). Frequencies of CYP3A5*1/*3 variants in a Moroccan population and effect on tacrolimus daily dose requirements in renal transplant patients. Genet Test Mol Biomarkers 16:644–7
   PubMed Web of Science ®Google Scholar
• Floyd MD, Gervasini G, Masica AL, et al. (2003). Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595–606
   PubMedGoogle Scholar
• Gabriel SB, Schaffner SF, Huy N, et al. (2002). The structure of haplotype blocks in the human genome. Science 296:2225–9
   PubMed Web of Science ®Google Scholar
• Ge JXWS, Chao SJ. (1997). Zhongguo yimin shi (The migration history of China). Fuzhou, China: Fujian People's Press
   Google Scholar
• Goddard KA, Hopkins PJ, Hall JM, Witte JS. (2000). Linkage disequilibrium and allele-frequency distributions for 114 single-nucleotide polymorphisms in five populations. Am J Hum Genet 66:216–34
   PubMed Web of Science ®Google Scholar
• Guilherme SK, Vargens DD, Ana Beatriz S, et al. (2014). Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population. PLoS One 9:e83472
   Google Scholar
• Hadjipanagi D, Chrysanthou S, Voskarides K, et al. (2014). Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population. BMC Res Notes 7:1–5
   PubMedGoogle Scholar
• Hiratsuka M, Takekuma Y, Endo N, et al. (2002). Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58:417–21
   PubMed Web of Science ®Google Scholar
• Hustert E, Haberl M, Burk O, et al. (2001). The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773–9
   PubMedGoogle Scholar
• Krishnakumar D, Umamaheswaran G, Kayathri D, et al. (2012). Genetic polymorphisms of drug‐metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Fundam Clin Pharmacol 26:295–306
   PubMed Web of Science ®Google Scholar
• Kudzi W, Dodoo AN, Mills JJ. (2010). Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 11:4113–20
   Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–91
   PubMed Web of Science ®Google Scholar
• Kurose K, Sugiyama E, Saito Y. (2012). Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 27:9–54
   PubMed Web of Science ®Google Scholar
• Lamba J, Hebert JM, Schuetz EG, et al. (2012). PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genom 22:73–7
   PubMed Web of Science ®Google Scholar
• Lee SJ, Goldstein JA. (2005). Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6:357–71
   PubMed Web of Science ®Google Scholar
• Li D, Zhang GL, Lou YQ, et al. (2007). Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther 32:89–95
   PubMed Web of Science ®Google Scholar
• Li HJ, Zhao XN, Qin F, et al. (1990). Abnormal hemoglobins in the Silk Road region of China. Hum Genet 86:231–5
   PubMed Web of Science ®Google Scholar
• Macphee IAM, Salim F, Maha M, et al. (2005). Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 79:499–502
   PubMed Web of Science ®Google Scholar
• Myrand SP, Sekiguchi K, Man MZ, et al. (2008). Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 84:347–61
   PubMed Web of Science ®Google Scholar
• Nelson DR, Zeldin DC, Hoffman SMG, et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1–18
   PubMedGoogle Scholar
• Ng PC, Henikoff S. (2002). Accounting for human polymorphisms predicted to affect protein function. Genome Res 12:436–46
   PubMed Web of Science ®Google Scholar
• Ng PC, Henikoff S. (2006). Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7:61–80
   PubMed Web of Science ®Google Scholar
• Paulussen A, Lavrijsen K, Bohets H, et al. (2000). Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10:415–24
   PubMedGoogle Scholar
• Roy JN, Lajoie J, Zijenah LS, et al. (2005). CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 33:884–7
   PubMed Web of Science ®Google Scholar
• Schuetz EG, Relling MV, Kishi S, et al. (2004). PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol Rev 56:159
   PubMedGoogle Scholar
• Sinues B, Vicente J, Fanlo A, et al. (2007). CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit 29:412–16
   PubMed Web of Science ®Google Scholar
• Thervet E, Loriot MS, Buchler M, et al. (2010). Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87:721–6
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389–430
   PubMed Web of Science ®Google Scholar
• van Schaik RHN, van der Heiden IP, van den Anker JN, Lindemans J. (2002). CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668–71
   PubMed Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, et al. (2004). Drug–drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Drug Metab Dispos 32:1201–8
   PubMed Web of Science ®Google Scholar
• Wojtczak A, Skretkowicz J. (2009). Clinical significance of some genetic polymorphisms of cytochrome P-450 subfamilies CYP2D, CYP2E and CYP3A – Part II. Polski Merkuriusz Lekarski Organ Polskiego Towarzystwa Lekarskiego 27:166–9
   PubMedGoogle Scholar
• Xiao-Cong Z, Ng CM, Barrett JS, et al. (2013). Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genom 23:251–61
   PubMed Web of Science ®Google Scholar
• Xu S, Huang W, Qian J, Jin L. (2008). Analysis of genomic admixture in Uyghur and its implication in mapping strategy. Am J Hum Genet 82:883–94
   PubMed Web of Science ®Google Scholar
• Yao YG, Kong QP, Wang CY, et al. (2005). Different matrilineal contributions to genetic structure of ethnic groups in the silk road region in china. Mol Biol Evol 21:2265–80
   Web of Science ®Google Scholar
• Yao YG, Lü XM, Luo HR, et al. (2000). Gene admixture in the Silk Road region of China: evidence from mtDNA and melanocortin 1 receptor polymorphism. Genes Genet Syst 75:173–8
   PubMed Web of Science ®Google Scholar
• Yong L, Jing Z, Yi-Xi W, et al. (2011). CYP3A5*3 and MDR-1 C3435T single nucleotide polymorphisms in six Chinese ethnic groups. Pharmazie 66:136–40
   PubMed Web of Science ®Google Scholar